AXDX

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported)                  December 8, 2022                                                                

Accelerate Diagnostics, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

(520) 365-3100

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

On December 8, 2022, Ron Price notified Accelerate Diagnostics, Inc. (the “Company”) of his decision to retire as the Company’s Chief Commercial Officer, Americas. Mr. Price’s last day with the Company is expected to be on January 6, 2023. Mr. Price’s retirement is for personal reasons and is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

In connection with Mr. Price’s resignation, on December 8, 2022, the Company and Mr. Price entered into a Separation Agreement and Release (the “Separation Agreement”), which provides that the Company will grant 104,338 restricted stock units to Mr. Price vesting on December 19, 2022 and subject to the terms and conditions of the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan. Pursuant to the Separation Agreement, Mr. Price has agreed to a general release of claims in favor of the Company, as well as certain restrictive covenants, including confidentiality, non-compete and non-solicitation provisions.

The foregoing description of the Separation Agreement is not complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed herewith as Exhibit 10.1 and incorporated herein by reference in its entirety.

(d)           Exhibits.  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Feb 2023 to Mar 2023

Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2022 to Mar 2023